Deciphera Pharmaceuticals (DCPH) Reports In-Line Q1 EPS
- Wall Street ends sharply higher after Powell comments
- Salesforce (CRM) shares slide despite topping earnings, revenue expectations
- Fed's Powell: Rate hikes to slow, but adjustment just beginning
- Snowflake shares plunge 13% despite Q3 beat
- Market turmoil and economic decline, before recovery in 2023, says JPM's Kolanovic
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q1 EPS of ($1.06), in-line with the analyst estimate of ($1.06). Revenue for the quarter came in at $19.96 million versus the consensus estimate of $22.59 million.
“We are excited by the continuing successful commercial launch of QINLOCK in the U.S. as we solidify its position among GIST prescribers and patients and expand access to this important medicine globally. We also remain focused on realizing QINLOCK’s potential in earlier lines of therapy,” said Steve Hoerter, President and Chief Executive Officer of Deciphera. “We expect the INTRIGUE Phase 3 top-line results in the fourth quarter of this year and believe QINLOCK has the potential to transform the treatment of GIST for this larger, second-line patient population. Building on our commitment to fully explore the potential of QINLOCK to benefit patients with GIST, we are excited to announce today our plans to initiate a Phase 1b/2 study combining QINLOCK with binimetinib, an approved MEK inhibitor. Our enthusiasm for this combination is based on compelling pre-clinical data showing that this combination can induce apoptosis and has the potential to deepen and prolong responses.”
Mr. Hoerter continued, “We remain very pleased with the progress and growth for the balance of our pipeline, including the upcoming initiation of the Phase 1 study for our potential first-in-class ULK kinase inhibitor, DCC-3116, in patients with cancers driven by mutant RAS or RAF genes. We look forward to presenting updated data from both the vimseltinib and rebastinib programs in the coming months and plan to finalize registration-enabling studies for both programs before the end of the year.”
For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Salesforce (CRM) Tops Q3 EPS by 18c, Offers Guidance
- Yext, Inc. (YEXT) Tops Q3 EPS by 4c
- Box (BOX) Tops Q3 EPS by 1c; Guides
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!